Neurology

doi: 10.25005/2074-0581-2019-21-3-408-414
STRATEGY OF DIFFERENTIATED MULTI-STAGE THERAPY OF PROXIMAL SPINAL AMIOTROPHY IN CHILDREN

M.R. Shaymurzin

Republican Clinical Center for Neurorehabilitation, Donetsk, Donetsk People’s Republic

Objective: To assess the results of the treatment of spinal muscular atrophy (SMA) in children using international scales of physical capacity assessment and computer electroneuromyography on different stages of the disease.

Methods: 95 children with a genetically confirmed diagnosis of proximal SMA from Donetsk region and other regions of Ukraine, as well as neighboring countries were under observation. All patients, depending on the therapy, were divided into two groups: the main group consisted of 65 children (68.4%), who received treatment based on the method developed by us; the control group comprised 30 children (31.6%) who received general therapy incorporating drugs from the metabolite group in age dosages and symptomatic drugs.

Results: An interim evaluation of the effectiveness of therapy was carried out after 2 years, the final assessment – based on 4 years of catamnesis observation by statistical processing of patient’s physical performance assessments. According to the interim and final results, the severity of the clinical condition is reliably higher in patients of the control group with the SMA II and III type.

Conclusions: A comprehensive approach to the evaluation of the treatment of SMA, both from a clinical and additional research perspective, effectively promotes differentiated phases selecting therapies aimed at slowing down the pathological process, preventing complications and improving the quality of life.

Keywords: Spinal muscular atrophy, children, electroneuromyography , non-drug and drug therapy.

Download file:


References
  1. Pobedinskaya AI, Buyanova GV, Maslennikova NV, Smirnov DS. Spinal’nye myshechnye atrofii detskogo vozrasta [Spinal muscular atrophy of childhood]. Pediatricheskiy vestnik Yuzhnogo Urala. 2015;2:79-82.
  2. Zabnenkova VV, Dadali EL, Polyakov AV. Proksimal’naya spinal’naya myshechnaya atrofiya tipov I-IV: osobennosti molekulyarno-geneticheskoy diagnostiki [Proximal spinal muscular atrophy of types I-IV: features of molecular genetic diagnosis.]. Nervno-myshechnye bolezni. 2013;3:27-31.
  3. Kruitwagen-Van Reenen ET, van der Pol L, Schröder C, Wadman RI, van den Berg LH, Visser-Meily JMA, Post MWM. Social participation of adult patients with spinal muscular atrophy: Frequency, restrictions, satisfaction, and correlates. Muscle Nerve. 2018;58(6):805-11.
  4. Van Groenestijn AC, Kruitwagen-van Reenen ET, Visser-Meily JM, van den Berg LH, Schröder CD. Associations between psychological factors and health-related quality of life and global quality of life in patients with ALS: a systematic review. Health Qual Life Outcomes. 2016;14(1):107.
  5. Shaymurzin MR. Spinal’nye myshechnye atrofii u detey: epidemiologiya, fenotipicheskie osobennosti i sovremennye vozmozhnosti ranney kliniko-instrumental’noy diagnostiki [Spinal muscular atrophy in children: epidemiology, phenotypic features and modern capabilities of early clinical and instrumental diagnostics.]. Mezhdunarodnyy nevrologicheskiy zhurnal. 2019;4:98-105.
  6. Ross LF, Kwon JM. Spinal muscular atrophy: past, present, and future. Neoreviews. 2019;20(8):e437-e451.
  7. Sokolova MG, Aleksandrov NYu, Lobzin SV. Spinal’naya myshechnaya atrofiya u detey: etiologiya, patogenez, diagnostika i printsipy lecheniya [Spinal muscular atrophy in children: etiology, pathogenesis, diagnosis and treatment principles]. Vestnik SZGMU. 2013;5(4):108-14.
  8. Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J Med Econ. 2019;4:1-10.
  9. Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831-46.
  10. Dolgova IN, Karpov SM, Minaeva OA. Nasledstvennye faktory myshechnoy gipotonii u detey [Hereditary factors of muscle hypotension in children.]. Meditsinskiy vestnik Severnogo Kavkaza. 2018;4:609-11.
  11. Srivastava G, Srivastava P. Spinal muscular dystrophy – a revisit of the diagnosis and treatment modalities. Int J Neurosci. 2019;4:1-16.
  12. Dubowitz V. Spinal muscular atrophy revisited. Neuromuscul Disord. 2019;29(6):413-4.
  13. Vaidya S, Boes S. Measuring quality of life in children with spinal muscular atrophy: a systematic literature review. Qual Life Res. 2018;27(12):3087-94.
  14. Shaymurzin MR, Yakhyaeva ZI. Diagnosticheskie vozmozhnosti ranney identifikatsii spinal’nykh amiotrofiy i perspektivy vyyavleniya markyorov progredientsii zabolevaniya u detey [Diagnostic possibilities of early identification of spinal amyotrophy and prospects for identifying markers of disease progression in children]. Vestnik meditsinskogo instituta. 2018;1:40-50.
  15. Van Es MA, Kruitwagen-van Reenen ET, Schröder CD, Pasterkamp RJ, Veldink JH, van den Berg LH. Amyotrophic lateral sclerosis, a heterogeneous disorder. Ned Tijdschr Geneeskd. 2016;160:A9658.
  16. Saffari A, Weiler M, Hoffmann GF, Ziegler A. Gene therapies for neuromuscular diseases. Nervenarzt. 2019;90(8):809-16.
  17. Pulst SM. Antisense therapies for neurological diseases. Nervenarzt. 2019;90(8):781-6.
  18. High KA, Roncarolo MG. Gene therapy. N Engl J Med. 2019;381(5):455-64.
  19. Landfeldt E, Edström J, Sejersen T, Tulinius M, Lochmüller H, Kirschner J. Quality of life of patients with spinal muscular atrophy: A systematic review. Eur J Paediatr Neurol. 2019;23(3):347-56.
  20. Vaidya S, Boes S. Measuring quality of life in children with spinal muscular atrophy: a systematic literature review. Qual Life Res. 2018;27(12):3087-94.
  21. Kruitwagen-Van Reenen ET, Wadman RI, Visser-Meily JM, van den Berg LH, Schröder C, van der Pol WL. Correlates of health related quality of life in adult patients with spinal muscular atrophy. Muscle Nerve. 2016;54(5):850-5.
  22. Kim HY, Kim H, Baik W. Biological markers of mesenchymal stromal cells as predictors of response to autologous stem cell transplantation in patients with amyotrophic lateral sclerosis: an investigator-initiated trial and in vivo study. Stem Cells. 2014;32(10):24-31.
  23. Vuillerot C, Payan C, Iwaz J, Ecochard R, Bérard C. Responsiveness of the motor function measure in patients with spinal muscular atrophy. Arch Phys Med Rehabil. 2013;94(8):1555-61.
  24. Oreshkov AB, Abdulrakhim M. Ortoterapiya i klinicheskoe ortezirovanie patsientov so spinal’nymi myshechnymi atrofiyami [Orthotherapy and clinical orthosis of patients with spinal muscular atrophy]. Rossiyskiy vestnik perinatologii i pediatrii. 2015;4:223-4.

Authors informations:

Shaymurzin Mark Rafisovich Candidate of Medical Sciences, Head of the Clinical Diagnostic Department, Republican Clinical Center for Neurorehabilitation ORCID ID: 0000-0003-3770-6851 Author ID: 1040319

Address for correspondence:

Shaymurzin Mark Rafisovich
Candidate of Medical Sciences, Head of the Clinical Diagnostic Department, Republican Clinical Center for Neurorehabilitation

83062, Donetsk People’s Republic, Donetsk, Il’ich Ave, 80a

Tel.: +380 (713) 360673

E-mail: mark04031980@mail.ru

Materials on the topic: